US-Irish firm Medtronic (NYSE: MDT) has announced that it has received CE (Conformité Européenne) Mark approval in the European Union (EU) and the United Kingdom (UK) for its BrainSense Adaptive deep brain stimulation (aDBS) and BrainSense Electrode Identifier (EI). This approval marks a significant breakthrough in the treatment of Parkinson’s disease, offering new hope to patients suffering from this debilitating condition.
Deep Brain Stimulation: A Therapeutic Milestone
Deep brain stimulation (DBS) is a therapeutic method that involves implanting electrodes in the brain to regulate brain activity through the transmission of electrical signals. It is primarily used to treat Parkinson’s disease, severe depression, and other motor disorders. DBS has been particularly effective in significantly improving symptoms such as tremors, muscle stiffness, and bradykinesia in Parkinson’s disease patients, enhancing their quality of life.
BrainSense: Innovations in DBS Technology
Compared to traditional DBS systems, Medtronic’s BrainSense technology represents a significant innovation in both treatment principles and therapeutic effects. The BrainSense system features a closed-loop design, which allows for real-time monitoring of the patient’s brain activity. This advanced feature enables the system to automatically adjust brain stimulation parameters, providing a more personalized and responsive treatment approach. The CE Mark approval for BrainSense aDBS and EI in the EU and UK underscores Medtronic’s commitment to advancing medical technology and improving patient outcomes in the field of neurology.-Fineline Info & Tech
